Skip to main content
eScholarship
Open Access Publications from the University of California

UCSF

UC San Francisco Electronic Theses and Dissertations bannerUCSF

Examining the efficacy of various novel radiotherapies on prostate cancer cell lines

Abstract

Current treatments for prostate cancer, such as chemotherapy and androgen receptor signaling inhibitors, have varying success rates with unpredictable outcomes. As a result, there is a need for the development of novel targeted therapies which can provide positive responses from patients. Radioligand therapy (RLT) in combination with poly (ADP-ribose) polymerase (PARP) inhibitors has shown efficacy in preliminary in vitro studies. In this study, we will use RLT with beta emitter 177-Lu and alpha emitters 227-Th and 225-Ac conjugated to a CD46 targeting antibody, in addition to Niraparib or Talazoparib as the PARP inhibitor. MTT and colony forming assays were performed on two prostate cancer cell lines. 225-Ac-YS5 in combination with Talazoparib showed a promising ZIP synergy score of 25.35, indicating that the two work synergistically to provide better therapeutic outcomes. After in vitro efficacy, we will test in murine models, with a future goal of a human clinical trial.

Main Content
For improved accessibility of PDF content, download the file to your device.
Current View